Technological Platforms
Sungen Core Technologies
Sungen Biomedical Won the First Prize of Beijing Science and Technology Progress Award, Demonstrating Great Scientific Research Capacity
In April 2024, the Beijing Municipal People s Government issued the Decision on the Beijing Municipal Science and Technology Award in 2023. The project of Construction of a transformation sy...
From Acceleration of FIC Antibodies Research by AI to Exploration of New Quality Productivity in the Biomedical Industry
New quality productivity is a new concept first proposed by JinPing Xi during his investigation in Heilongjiang in September 2023, emphasizing that "integrating scientific and technological innov...
Co-operation to Create a New Chapter in the Research and Development of Biological Innovative Drugs for Cardiovascular Diseases
On November 20, 2023, Mr. Lin Changqing, Chairman and president of Beijing Hotgen Biotech Co., Ltd., Professor Du Jie, President of Beijing Antai Institute of Cardiovascular Medicine, and Professor Su...
The Official Opening Ceremony of the 'National Human Brain Health Project' Joint Laboratory was Held in Beijing
On October 31, 2023, the opening ceremony of the "National Human Brain Health Project" joint laboratory was initiated by Beijing Hotgen Biotech Co., LTD. ( "Hotgen Biotech"), Shenz...
Sungen Biomedical and Taizhou People's Hospital Officially Signed a Contract for Integration and Development
On January 3, 2024, Taizhou People's Hospital Affiliated to Nanjing Medical University held a conference on "Integrated Development of Hospital and Enterprise - Innovation and Transformation&...
An Article in Nature Reveals that the ASGR1-GP73 Axis is a Potential Therapeutic Target for Liver Injury
Recently, the new mechanism of GP73 in liver injury was published in Nature Communications by Professor Sun Zhiwei and Dr. Gao Qi of Sungen Biomedical R&D team，together with Xijing Hospital of Air For...
'X-Gen AI New Drug Discovery and Design Research Center' Published in PLOS Computational Biology
Recently, The X-Gen AI New Drug Discovery and Design Research Center has published a paper titled" Dual Computational and Experimental Strategy to Enhance TSLP Antibody Affinity for Improved Asth...
Xinhua Finance: AI Enables 'China's Pharmaceutical Valley' to Accelerate the 'New' Way
In recent years, Daxing biomedical industry Base, known as "China's Pharmaceutical Valley", has introduced high-tech enterprises and focused on promoting the integration of artificial in...
Economic Daily: 'China's Pharmaceutical Valley' Relies on AI to Innovate and Develop—Beijing Daxing Technology Enables the Biomedical Industry
It takes at least 10 years and costs $1 billion to successfully develop a new drug, which is recognized as "double ten laws" in the field of new drug research and development. As new technol...
